"Building Bridges: Insights into Business Development and Partnerships in Biopharma."

Anjali Kumar - VP & Head of Business Development - Cellarity

In this article, we feature Anjali Kumar, a distinguished leader with over 25 years of experience in the biopharmaceutical industry. Currently, she serves as VP and Head of Business Development at Cellarity, a Flagship Pioneering company.

Anjali's impressive career includes roles at major companies such as Johnson & Johnson, Shire, Wyeth, and Pharmacia & Upjohn, as well as emerging firms like Flexion Therapeutics and Critical Therapeutics.

She has significantly contributed to drug discovery and development, leading over 50 deep integrated opportunity assessments and numerous transactions including M&A and license agreements.

At Cellarity, she drives business development for a unique AI/ML-enabled platform.

Additionally, Anjali is a member of the External Advisory Board at Georgia Tech and holds a PhD in Bioengineering from the same institution.

Join us as Anjali shares her journey, the challenges and opportunities in the industry, and her vision for the future. We explore her insights on building successful partnerships and driving innovation in biopharma.

"Building Bridges: Insights into Business Development and Partnerships in Biopharma."

Ravneesh Sachdev - Partner and Head of Business Development at Apple Tree Partners

We delve into the career and insights of Ravneesh Sachdev, a leading figure in biopharma business development. Currently a Partner and Head of Business Development at Apple Tree Partners, a venture capital firm focused on life sciences investment, Ravneesh shares his extensive experience in shaping strategic partnerships and driving innovation in the industry. From his pivotal roles at Acceleron Pharma and Sage Therapeutics to his contributions at Pfizer and other major companies, Ravneesh offers a wealth of knowledge on navigating challenges and seizing opportunities in biopharma.

Join us to explore his journey, key accomplishments, and vision for the future of biopharma partnerships.